Cook R - Search Results

1

Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints.

Major PP, Cook R. Major PP, et al. Among authors: cook r. Am J Clin Oncol. 2002 Dec;25(6 Suppl 1):S10-8. doi: 10.1097/00000421-200212001-00003. Am J Clin Oncol. 2002. PMID: 12562046 Review.

2

Methodology for treatment evaluation in patients with cancer metastatic to bone.

Cook RJ, Major P. Cook RJ, et al. J Natl Cancer Inst. 2001 Apr 4;93(7):534-8. doi: 10.1093/jnci/93.7.534. J Natl Cancer Inst. 2001. PMID: 11287447

3

Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.

Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, Lee KA, Zheng M, Hei YJ, Coleman RE. Brown JE, et al. J Natl Cancer Inst. 2005 Jan 5;97(1):59-69. doi: 10.1093/jnci/dji002. J Natl Cancer Inst. 2005. PMID: 15632381

4

Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid.

Coleman RE, Major P, Lipton A, Brown JE, Lee KA, Smith M, Saad F, Zheng M, Hei YJ, Seaman J, Cook R. Coleman RE, et al. Among authors: cook r. J Clin Oncol. 2005 Aug 1;23(22):4925-35. doi: 10.1200/JCO.2005.06.091. Epub 2005 Jun 27. J Clin Oncol. 2005. PMID: 15983391

5

Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer.

Cook RJ, Coleman R, Brown J, Lipton A, Major P, Hei YJ, Saad F, Smith MR. Cook RJ, et al. Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3361-7. doi: 10.1158/1078-0432.CCR-06-0269. Clin Cancer Res. 2006. PMID: 16740758 Clinical Trial.

6

Multistate analysis of skeletal events in patients with bone metastases.

Cook RJ, Major P. Cook RJ, et al. Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6264s-6269s. doi: 10.1158/1078-0432.CCR-06-0654. Clin Cancer Res. 2006. PMID: 17062711 Review.

7

Clinical utility of biochemical markers of bone metabolism for improving the management of patients with advanced multiple myeloma.

Lipton A, Cook RJ, Coleman RE, Smith MR, Major P, Terpos E, Berenson JR. Lipton A, et al. Among authors: cook rj. Clin Lymphoma Myeloma. 2007 Mar;7(5):346-53. doi: 10.3816/CLM.2007.n.011. Clin Lymphoma Myeloma. 2007. PMID: 17562244 Review.

8

Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer.

Smith MR, Cook RJ, Coleman R, Brown J, Lipton A, Major P, Hei YJ, Saad F. Smith MR, et al. Among authors: cook rj. Urology. 2007 Aug;70(2):315-9. doi: 10.1016/j.urology.2007.03.071. Urology. 2007. PMID: 17826496 Free PMC article. Clinical Trial.

9

Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity.

Lipton A, Cook RJ, Major P, Smith MR, Coleman RE. Lipton A, et al. Among authors: cook rj. Oncologist. 2007 Sep;12(9):1035-43. doi: 10.1634/theoncologist.12-9-1035. Oncologist. 2007. PMID: 17914073 Free article. Clinical Trial.

10

Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity.

Hirsh V, Major PP, Lipton A, Cook RJ, Langer CJ, Smith MR, Brown JE, Coleman RE. Hirsh V, et al. Among authors: cook rj. J Thorac Oncol. 2008 Mar;3(3):228-36. doi: 10.1097/JTO.0b013e3181651c0e. J Thorac Oncol. 2008. PMID: 18317064 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,538 results

Search Page

Filters